Histogen to Present at the H.C. Wainwright Global Life Sciences Virtual Conference
Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company, announced its participation in the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company, announced its participation in the H.C. Wainwright Global Life Sciences Virtual Conference. The presentation will be available for on-demand listening starting March 9, 2021, at 7:00 AM Eastern Time. Histogen focuses on developing innovative restorative therapeutics that harness the body's natural repair mechanisms. Their technology platform features cell conditioned media and extracellular matrix materials for various therapeutic applications, including hair growth and joint regeneration.
Details
News Market Reaction – HSTO
The recorded move for HSTO in the trading session of this news was -0.85%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced it will present at the H.C. Wainwright Global Life Sciences Virtual Conference.
The presentation will be available for on-demand listening beginning Tuesday, March 9, 2021 at 7:00 AM Eastern Time and can be accessed using the link https://journey.ct.events/view/7966236d-e7ae-450b-b02f-b0720cfcf78a.
About Histogen
Histogen Inc. is a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. Histogen’s innovative technology platform utilizes cell conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells. Histogen’s proprietary, reproducible manufacturing process provides targeted solutions across a broad range of therapeutic indications including hair growth, dermal rejuvenation, joint cartilage regeneration and spinal disk repair. For more information, please visit www.histogen.com.
CONTACT:
Susan A. Knudson
Executive Vice President & CFO
Histogen Inc.
ir@histogen.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.